

A large, solid red circle is centered on a dark gray background. Inside the circle, the letters 'PSI' are written in a bold, black, sans-serif font. The letters are slightly shadowed, giving them a three-dimensional appearance as if they are floating within or attached to the surface of the circle.

PSI

Time has failed us

- Two years into the pandemic, and 20 months proposal. Uncountable lives lost.
- Pharma companies, benefited from it, this was their game all along.
- Shift in strategy: Redirect energies away from TRIPS Waiver and save the face of the WTO

'We Are Choosing Death': Byanyima, Stiglitz Slam WTO Inaction on Vaccine Patents

Winnie Byanyima, the head of UNAIDS, said rich countries have chosen to "protect the monopolies and profits of pharma companies, and millions of people have died who shouldn't have died."

"The drug companies did not want a quick response," said Stiglitz. "The slower the response, the higher their profits. More people died, but that's not their concern. Their concern was profits over people's lives."

Pharma under pressure

Nov 2021: Towards WTO Ministerial Conf.

- Global TRIPS Waiver Campaign steps up visibility
- Unified and visible union voice, [Council of Global Unions](#) Statement.
 - Moderna commits vax doses and manufacturing in Africa
 - Pfizer commits voluntary license with Medicines Patent Pool

May 2022: WTO talks take new turn

- Global TRIPS Waiver campaign exposes new Covid-19 text
- [PSI Statement](#) rejecting the text and PSI affiliate [protest at Davos](#)
 - Pfizer commits medicines, vax to 45 LICs



2022: Pfizer commits medicines, vaccines to 45 low income countries

Forum (WEF) 2022: The initiative by Pfizer was launched at the World Economic Forum Annual Meeting in Davos 2022

Too little, too late

- **Too limited ambition.** From expansion of production by providing simplified pathways to clarifying existing caveats that enable gov to sidestep patents.
- **Too narrow scope.** From all the health products to prevent, contain and treat COVID-19 to just vaccines, and possibility to expansion with a very limited window.
- **Unpracticable coverage.** From a range of IP privileges relevant for bringing a health product to the public to only patents, on a case-by-case basis, if necessary to address the COVID-19 pandemic.
- Forces are at play to make it worse.

HEALTH WORKERS AROUND THE WORLD CALL ON WTO MEMBERS TO PUT PEOPLE'S HEALTH BEFORE BIG PHARMA'S PROFITS. SHARE COVID-19 VACCINES AND TREATMENTS



SUPPORT THE #TRIPSWAIVER #PEOPLESVACCINE

Key take aways

- We need a *permanent mechanism for automatic suspension of IP privileges* when a Public health emergency of international concern is announced. A crisis-by-crisis waiver demand is unpracticable.
- Health products required for public health are common public goods and require public direction in production. We need *public-led local production of vaccines and medicines*.
- Health governance, policy can't be left to trade officials. This is *WHO's mandate, not WTO's*.
- We need *change in the innovation system*. Incentivizing research and innovation with monopoly privileges as main reward works against public health, as highlighted by
 - UN High level panel on access to medicines and
 - WHO global strategy on public health, innovation and IP (GSPOA)

Thank you

<https://publicservices.international>

susana.barria@world-psi.org